High incidence of female reproductive tract cancers in FA-deficient HPV16-transgenic mice correlates with E7's induction of DNA damage response, an activity mediated by E7's inactivation of pocket proteins

Oncogene

Volumn 33, Issue 26, 2014, Pages 3383-3391

  Park, J W ^a   Shin, M K ^a   Lambert, P F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Fanconi anemia; HPV positive cancer; HPV16 E7

Indexed keywords

BINDING PROTEIN; HISTONE H2AX; P53 BINDING PROTEIN 1; PROTEIN E6; PROTEIN E7; PROTEIN P107; PROTEIN P130; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; FANCONI ANEMIA PROTEIN; GAMMA-H2AX PROTEIN, MOUSE; HISTONE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN P53; RBL1 PROTEIN, MOUSE; RBL2 PROTEIN, MOUSE; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; DNA DAMAGE; FANCONI ANEMIA; FEMALE; FEMALE GENITAL TRACT CANCER; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN INDUCTION; SQUAMOUS CELL CARCINOMA; TRANSGENIC MOUSE; UTERINE CERVIX CANCER; VAGINA CANCER; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR;

HUMAN PAPILLOMAVIRUS; MUS; MUS MUSCULUS;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DNA DAMAGE; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HISTONES; HUMAN PAPILLOMAVIRUS 16; MICE; MICE, KNOCKOUT; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA-LIKE PROTEIN P107; RETINOBLASTOMA-LIKE PROTEIN P130; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 84903607680     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.327     Document Type: Article

References (59)

1. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101: 1249-1256.
2. Garner E, Smogorzewska A. Ubiquitylation and the Fanconi anemia pathway. FEBS Lett 2011; 585: 2853-2860.
3. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2001; 2: 446-457.
4. Crossan GP, Patel KJ. The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA. J Pathol 2012; 226: 326-337.
5. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005; 19: 2925-2940.
6. Knipscheer P, Raschle M, Smogorzewska A, Enoiu M, Ho TV, Scharer OD et al. The Fanconi anemia pathway promotes replication-dependent DNA interstrand crosslink repair. Science 2009; 326: 1698-1701.
7. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet [Review] 2007; 370: 890-907.
8. Watson M, Saraiya M, Ahmed F, Cardinez CJ, Reichman ME, Weir HK et al. Using population-based cancer registry data to assess the burden of human papillomavirus- associated cancers in the United States: overview of methods. Cancer 2008; 113(10 Suppl): 2841-2854.
9. Shin MK, Balsitis S, Brake T, Lambert PF. Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. Cancer Res 2009; 69: 5656-5663.
10. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8: 4099-4105.
11. Shin MK, Sage J, Lambert PF. Inactivating all three rb family pocket proteins is insufficient to initiate cervical cancer. Cancer Res 2012; 72: 5418-5427.
12. Shin MK, Pitot HC, Lambert PF. Pocket proteins suppress head and neck cancer. Cancer Res 2012; 72: 1280-1289.
13. Balsitis SJ, Sage J, Duensing S, Munger K, Jacks T, Lambert PF. Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol 2003; 23: 9094-9103.
14. Collins AS, Nakahara T, Do A, Lambert PF. Interactions with pocket proteins contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle. J Virol 2005; 79: 14769-14780.
15. McLaughlin-Drubin ME, Munger K. The human papillomavirus E7 oncoprotein. Virology 2009; 384: 335-344.
16. Shai A, Brake T, Somoza C, Lambert PF. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 2007; 67: 1626-1635.
17. Genther SM, Sterling S, Duensing S, Munger K, Sattler C, Lambert PF. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J Virol 2003; 77: 2832-2842.
18. Wang SS, Bratti MC, Rodriguez AC, Herrero R, Burk RD, Porras C et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis 2009; 199: 20-30.
19. Juko-Pecirep I, Ivansson EL, Gyllensten UB. Evaluation of Fanconi anaemia genes FANCA, FANCC and FANCL in cervical cancer susceptibility. Gynecol Oncol 2011; 122: 377-381.
20. Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002; 62: 7075-7082.
21. Spardy N, Duensing A, Charles D, Haines N, Nakahara T, Lambert PF et al. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. J Virol 2007; 81: 13265-13270.
22. Hoskins EE, Morris TA, Higginbotham JM, Spardy N, Cha E, Kelly P et al. Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture. Oncogene 2009; 28: 674-685.
23. Park JW, Pitot HC, Strati K, Spardy N, Duensing S, Grompe M et al. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPVassociated head and neck cancer. Cancer Res 2010; 70: 9959-9968.
24. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 2003; 63: 4862-4871.
25. Alter BP, Greene MH, Velazquez I, Rosenberg PS. Cancer in Fanconi anemia. Blood 2003; 101: 2072.
26. Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA 2006; 103: 14152-14157.
27. Brake T, Connor JP, Petereit DG, Lambert PF. Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer. Cancer Res 2003; 63: 8173-8180.
28. Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ et al. Fundamental differences in cell cycle deregulation in human papillomaviruspositive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-4619.
29. Begum S, Cao D, Gillison M, Zahurak M, Westra WH. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 2005; 11: 5694-5699.
30. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363: 1488-1489.
31. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002; 100: 2414-2420.
32. Pichierri P, Rosselli F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J 2004; 23: 1178-1187.
33. Zhang QS, Marquez-Loza L, Eaton L, Duncan AW, Goldman DC, Anur P et al. Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol. Blood 2010; 116: 5140-5148.
34. Duensing S, Duensing A, Flores ER, Do A, Lambert PF, Munger K. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J Virol 2001; 75: 7712-7716.
35. Duensing S, Munger K. Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability. Oncogene 2002; 21: 6241-6248.
36. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 1994; 8: 666-677.
37. Huyen Y, Zgheib O, Ditullio Jr RA, Gorgoulis VG, Zacharatos P, Petty TJ et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature 2004; 432: 406-411.
38. Huh KW, DeMasi J, Ogawa H, Nakatani Y, Howley PM, Munger K. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sci USA 2005; 102: 11492-11497.
39. Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res 2008; 68: 9928-9934.
40. Liu TX, Howlett NG, Deng M, Langenau DM, Hsu K, Rhodes J et al. Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. Dev Cell 2003; 5: 903-914.
41. Houghtaling S, Granville L, Akkari Y, Torimaru Y, Olson S, Finegold M et al. Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Res 2005; 65: 85-91.
42. Shai A, Pitot HC, Lambert PF. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res 2008; 68: 2622-2631.
43. Sun A, Bagella L, Tutton S, Romano G, Giordano A. From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem 2007; 102: 1400-1404.
44. Mayol X, Grana X, Baldi A, Sang N, Hu Q, Giordano A. Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 1993; 8: 2561-2566.
45. Hannon GJ, Demetrick D, Beach D. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. Genes Dev 1993; 7: 2378-2391.
46. Ewen ME, Ludlow JW, Marsilio E, DeCaprio JA, Millikan RC, Cheng SH et al. An N-terminal transformation-governing sequence of SV40 large T antigen contributes to the binding of both p110Rb and a second cellular protein, p120. Cell 1989; 58: 257-267.
47. Dyson N, Buchkovich K, Whyte P, Harlow E. The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. Cell 1989; 58: 249-255.
48. Simpson DS, Mason-Richie NA, Gettler CA, Wikenheiser-Brokamp KA. Retinoblastoma family proteins have distinct functions in pulmonary epithelial cells in vivo critical for suppressing cell growth and tumorigenesis. Cancer Res 2009; 69: 8733-8741.
49. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res 2010; 70: 3877-3883.
50. Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev 1998; 12: 1599-1609.
51. Ho VM, Schaffer BE, Karnezis AN, Park KS, Sage J. The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene 2009; 28: 1393-1399.
52. Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002; 109: 459-472.
53. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog 2009; 5: e1000318.
54. de Araujo MR, Rubira-Bullen IR, Santos CF, Dionisio TJ, Bonfim CM, De Marco L et al. High prevalence of oral human papillomavirus infection in Fanconi's anemia patients. Oral Dis 2011; 17: 572-576.
55. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68: 362-372.
56. Hoskins EE, Morreale RJ, Werner SP, Higginbotham JM, Laimins LA, Lambert PF et al. The Fanconi anemia pathway limits human papillomavirus replication. J Virol 2012; 86: 8131-8138.
57. Song S, Pitot HC, Lambert PF. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol 1999; 73: 5887-5893.
58. Herber R, Liem A, Pitot H, Lambert PF. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol 1996; 70: 1873-1881.
59. Houghtaling S, Timmers C, Noll M, Finegold MJ, Jones SN, Meyn MS et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev 2003; 17: 2021-2035.